infliximab IBD
Selected indexed studies
- Infliximab in young paediatric IBD patients: it is all about the dosing. (Eur J Pediatr, 2020) [PMID:32813123]
- Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. (J Crohns Colitis, 2024) [PMID:38656784]
- Predictive biomarkers for anti-TNF alpha therapy in IBD patients. (J Transl Med, 2024) [PMID:38493113]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients. (2024) pubmed
- Therapeutic drug monitoring in inflammatory bowel disease: recent developments. (2024) pubmed
- Infliximab in young paediatric IBD patients: it is all about the dosing. (2020) pubmed
- Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. (2024) pubmed
- Predictive biomarkers for anti-TNF alpha therapy in IBD patients. (2024) pubmed
- Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. (2018) pubmed
- Infliximab levels and antibodies in IBD-related peripheral arthralgia. (2020) pubmed
- Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch? (2020) pubmed
- Nutritional Status and Its Detection in Patients with Inflammatory Bowel Diseases. (2023) pubmed
- Adenosine-generating CD39(+) plasmablasts predispose to successful infliximab therapy in pediatric IBD. (2025) pubmed